Yue-Wei Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yue-Wei Zhang has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
Ding Zhongyi
Cancer Interventional Center, Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning, China
1 shared publication- Guangsheng Zhao
Department of Interventional Therapy, Linyi Cancer Hospital, Linyi, Shandong Province, China
1 shared publication - Jun Zhou
Cancer Interventional Center, Affiliated Zhongshan Hospital of Dalian University
1 shared publication Liu Song
Dalian Medical University, Dalian, Liaoning, China
1 shared publication- Song Liu
Dalian Medical University, Dalian, Liaoning 116044, P.R. China
1 shared publication Tang Shunxiong
Cancer Interventional Center, Affiliated Zhongshan Hospital of Dalian University, Dalian, Liaoning, China
1 shared publication
Latest Publications
- Open Access
- 7 January 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1693092
TACE combined with sorafenib induces complete remission in an elderly patient with hepatocellular carcinoma, hepatic venous tumor thrombus, and diffuse lung metastasis: a case study and literature review
Hepatocellular carcinoma (HCC) with hepatic venous tumor thrombus (HVTT) and synchronous lung metastases has a poor prognosis and limited treatment options. We present a 70-year-old male with chronic hepatitis B and BCLC stage C HCC, featuring a large liver tumor (14×12×10 cm), HVTT, and diffuse lung metastases. The patient was treated with transarterial gene embolization (TAGE) using gelatin sponge microparticles and rAd-p53 (Gendicine ® ), followed by sorafenib. Imaging showed rapid tumor necrosis at 4 days, significant reduction of lung nodules at 4 weeks, and complete tumor necrosis with resolution of lung metastases at 15 weeks. The patient achieved complete remission and remains alive with 14-year survival.
- 7 January 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 15, 1693092
Open AccessTACE combined with sorafenib induces complete remission in an elderly patient with hepatocellular carcinoma, hepatic venous tumor thrombus, and diffuse lung metastasis: a case study and literature review
Hepatocellular carcinoma (HCC) with hepatic venous tumor thrombus (HVTT) and synchronous lung metastases has a poor prognosis and limited treatment options. We present a 70-year-old male with chronic hepatitis B and BCLC stage C HCC, featuring a large liver tumor (14×12×10 cm), HVTT, and diffuse lung metastases. The patient was treated with transarterial gene embolization (TAGE) using gelatin sponge microparticles and rAd-p53 (Gendicine ® ), followed by sorafenib. Imaging showed rapid tumor necrosis at 4 days, significant reduction of lung nodules at 4 weeks, and complete tumor necrosis with resolution of lung metastases at 15 weeks. The patient achieved complete remission and remains alive with 14-year survival.
- Open Access
- 25 September 2014
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 12 (1) , 300
Complete remission of diffuse hepatocellular carcinoma in a young adult after GSP-TACE: a case report
Hepatocellular carcinoma (HCC) is the most common primary tumor of the liver. It mostly occurs in older age groups (usually those 50 to 60 years old), and rarely in young adults. The survival rate of these young HCC patients is usually very low. The authors report a case of a 22-year old man with diffuse-type HCC who successfully achieved complete remission for 46 months after second transcatheter arterial chemoembolization using gelatin sponge particles (Eric Kang Pharmaceutical Technology Co., Ltd. Hangzhou, China) combined with pirarubicin.
- 25 September 2014
- Published by Springer Nature in World Journal of Surgical Oncology
- Vol. 12 (1) , 300
Open AccessComplete remission of diffuse hepatocellular carcinoma in a young adult after GSP-TACE: a case report
Hepatocellular carcinoma (HCC) is the most common primary tumor of the liver. It mostly occurs in older age groups (usually those 50 to 60 years old), and rarely in young adults. The survival rate of these young HCC patients is usually very low. The authors report a case of a 22-year old man with diffuse-type HCC who successfully achieved complete remission for 46 months after second transcatheter arterial chemoembolization using gelatin sponge particles (Eric Kang Pharmaceutical Technology Co., Ltd. Hangzhou, China) combined with pirarubicin.